recombinant adeno-associated virus vector vaccine (Applied Genetic Technologies)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namerecombinant adeno-associated virus vector vaccine (Applied Genetic Technologies)
Drug Alias NamerAAV1-CB-human AAT
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/Indicationsalpha 1-Antitrypsin Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBeacon Therapeutics Holdings Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeacon Therapeutics Holdings Ltd
Active IndicationsN/A
Inactive Indicationsalpha 1-Antitrypsin Deficiency

Other Information

ATC CodeN/A
Related LinksN/A